Imagion Biosystems September 2021 Investor Newsletter
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
16 September 2021
Imagion Biosystems September 2021 Investor Newsletter
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare
through the earlier detection of cancer, is pleased to provide its investors with its September 2021 Investor
Newsletter.
The newsletter details recent new company developments and activities, including:
• Message from the CEO, Mr Robert Proulx;
• Q&A with Jane Fox, Director of Breast Services at Monash Health, and Principal Investigator of the
MagSense® HER2 breast cancer clinical study;
• Expanding the MagSense® pipeline to brain cancer;
• IBX SAB member Dr Andrew Scott Appointed to VCCC Alliance;
• Imagion Biosystems 1H2021 Half-Year Report;
• Employment of Chief Development Officer; and
• Update on Nanoparticle Sales.
The investor newsletter can be viewed below. Imagion Biosystems normally distributes this update as an enewsletter. Investors can sign up to receive email updates at this link: http://ems.gs/3FuT0frcGxD
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1 408-905-7630
Australian Media & Investor Relations:
Evonne Grosso, WE Communications
egrosso@we-worldwide.com
+61 450 603 182
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
INVESTOR NEWSLETTER
ISSUE 15 - SEPTEMBER 2021
in detected cases once screening resumes,
only the cancer will, in some cases, be
more advanced. We applaud the Victorian
Government’s “dontwaitmate” campaign
to encourage maintaining best healthcare
practices and are looking forward to the
return of routine cancer screening for all.
Message from the CEO
Dear Shareholders,
I’m happy to share with you our latest Investor
Newsletter with updates on Imagion’s recent
activities.
Since our last Investor Newsletter in March,
the most important accomplishment for our
company has been our progression to “clinical
stage” with the start of our MagSense®
HER2 breast cancer Phase I study. Getting
into the clinic is a significant achievement
for any biotech company, and our efforts
now are focused on working diligently with
our investigators and advisors to ensure the
priority of recruitment and study endpoints
are met.
In March we had noted that Cancer Council
Victoria had been reporting a noticeable drop
in cancer screening and we were saddened
to see the August 9th article in the Sydney
Morning Herald indicating breast cancer
screening clinics were being shut down and
that more than 2500 cancer diagnoses were
likely missed due to the pandemic.
We’ve seen the pandemic effect the progress
of clinical studies globally, including the
ability for hospitals and staff to initiate
studies and access patients. And while we
are tackling these factors for our own firstever human trial, our broader concern is for
the health and welfare of Australians and
cancer patients globally. Delays in routine
screening will ultimately result in a surge
The constantly changing picture of regional
lockdowns has made it difficult to predict the
impact on timing and duration of our study
so we have focused on trying to increase the
number of sites and build awareness of the
study in the catchment areas. Our third site
(located in Brisbane) is actively screening
patients and we look forward to their
contribution to our study. The NSW site we
mentioned in our half-yearly results engages
with a substantive patient population and
is in the final steps of meeting their local
contractual and governance requirements
which will allow us to proceed with site
training and initiation of patient screening.
Our work to expand the MagSense® product
pipeline has also made progress in the
last few months. In addition to the CSIRO
funded collaboration with Monash University
researchers in prostate cancer (covered in
the last Newsletter), we have since added a
collaboration with Patrys Limited (ASX:PAB),
in which we are exploring the use of a Patrys’
deoxymab with our nanoparticles for brain
tumour imaging and diagnosis.
Lastly, I think the recent announcement of our
Joint Development Agreement with Global
Cancer Technology is worth mentioning.
GCT’s nanoscintillator technology has the
potential to improve the utility of low dose
radiation for the treatment of solid tumours
through x-ray induced phototherapy. We’re
excited to be part of this project and look
forward to lending our expertise to the
development of a new way of treating breast
cancers.
As we continue to push further forward
with recruitment for our clinical study and
the expansion of our product pipeline, I wish
to thank shareholders for their continued
support of the Company. Despite the short1
term challenges, we remain confident in our
path forward and look forward to continued
success together.
With best regards,
Robert Proulx,
President & CEO
In this issue:
Message from the CEO
Q&A with Jane Fox, Director
of Breast Services at Monash
Health, and Principal
Investigator of the MagSense’s
HER2 Breast Cancer clinical
study
Expanding the MagSense®
pipeline to brain cancer
IBX SAB member Dr Andrew
Scott Appointed to VCCC
Alliance
Half Year Report
Chief Development Officer
Nanoparticle Sales
INVESTOR NEWSLETTER
ISSUE 15 - SEPTEMBER 2021
Q&A with Jane Fox, Director of Breast Services
at Monash Health, and Principal Investigator of
the MagSense’s HER2 Breast
Cancer clinical study
With the Phase I study for the MagSense® HER2
imaging agent underway, we thought it would
be interesting to hear from the study’s Principle
Investigator, Jane Fox.
Why did you decide to get involved in the MagSense®
study?
There is a focus in several areas of cancer research in
determining who will, and who won’t benefit from particular treatments, with a desire to
avoid both undertreatment and overtreatment. My interest was piqued by the MagSense®
study because of the opportunity to personalise patient management with a focus on refining
the information available to medical, surgical and radiation oncologists. For example, when
there is uncertainty about whether there is a disease in the lymph nodes or not, it can make
planning neoadjuvant systemic therapy, or surgery or radiotherapy, more difficult. It would
be good to have more certainty about the nodal disease without the patient needing an
operation to obtain it.
IBX SAB member Dr
Andrew Scott appointed
to VCCC Alliance
The Board, Executive and clinical research
teams at Imagion Biosystems would like
to congratulate our Scientific Advisory
Board member, Dr Andrew Scott for his
appointment as Research Translation and
Commercialisation Lead for VCCC Alliance.
As a member of the Company’s Scientific
Advisory Board, Imagion has benefitted
from of Dr Scott’s experience in bridging
technology and innovation with healthcare
and clinical practice.
We wish Dr Scott all the best in his new
appointment and look forward to continuing
to work together.
What are some of the challenges you are seeing in recruiting patients for the study?
Remembering that HER2 positive cancers are about 15% of all the breast cancer diagnosed,
we are starting with a relatively small target population. While the full impact of COVID
remains to be seen, I think there is some reluctance to attend hospitals for more than necessary
care but we are continuing to screen all our eligible patients through our multidisciplinary
meetings and offering the study to all potential participants and are looking forward to the
new sites contributing to the study.
Chief Development Officer
We’re very pleased to welcome Dr Yalia
Jayalakshmi as Chief Development Officer
responsible for leading our global clinical
development strategy and execution.
Dr Jayalakshmi’s comes to Imagion with deep
background, knowledge and leadership in cancer
imaging and nanotechnology at a depth that is
not regularly seen in the industry. Her experience
spans drug, device, nanoparticle delivery and
diagnostic imaging products in oncology,
ophthalmology and other therapeutic areas for
companies such as Onyx Pharma, Genetech, and
Cygnus. Her most recent role was Vice President
Clinical Development at OncoNano Medicine.
We look forward to her providing leadership for our current MagSense® HER2 breast cancer
Phase I study, and all our future clinical programs.
2
Half Year Report
Imagion released its Appendix 4D Half Year
Financial Report to Shareholders in August
2021.
Detailing the Company’s milestones in the
H1 period, the release provides a further
update on the company’s financial reporting,
our MagSense® HER2 Breast Cancer
Clinical Trial and other initiatives.
You can read the Half Year Report here.
INVESTOR NEWSLETTER
ISSUE 15 - SEPTEMBER 2021
Expanding the MagSense® pipeline to brain cancer
In May, we extended our collaborative research program with Patrys Limited, in which Imagion is investigating the use of Patrys’ novel
deoxymabs in combination with the imaging capabilities of the MagSense® technology.
Our preliminary research has demonstrated that the Patrys PAT-DX1 molecule can be attached to the MagSense nanoparticles and provide
bio-functionality for targeting certain cancer cell lines.
A recently published article by Patrys and researchers from Yale University
School of Medicine indicated that PAT-DX1 is effective in targeting brain tumors
in animal studies. If we achieve positive research results using DX1 to have
targeted delivery of an imaging agent, Imagion has an exclusive option to license
the Patrys molecule for use in magnetic imaging.
Conventional MRI has been the standard modality to identify and localize
brain tumors for many years as MRI provides improved sensitivity compared
to CT. Gadolinium-based contrast agents are often used for brain imaging, but
recent concerns of both nephrotoxicity and neurotoxicity stemming from use of
gadolinium have been raised. Positron Emission Tomography (PET) is also used
for brain imaging due to its sensitivity and ability to co-register images with other
imaging modalities, but PET has low spatial resolution, radiation exposure, and
relatively high cost. A bio-safe contrast agent, such as MAG-DX1, could provide high sensitivity and specificity for detecting and monitoring
brain tumors.
You can read the announcement here.
Nanoparticle Sales
In 2019 we first reported that New Phase, an Israeli company developing a hyperthermia treatment for
cancer, had placed a standing order for our super-paramagnetic iron oxide nanoparticles, which they
incorporate into their Sarah Nanoparticle (SaNP). We’ve continued to supply our nanoparticles to New
Phase throughout 2020 and 2021, working closely with them as they progress their pre-clinical research
of the SaNP product.
We are pleased to report that we have recently received an updated purchase order for additional supply
of our nanoparticles for the remainder of 2021. We look forward to continuing to work closely with them
in anticipation of transitioning their SaNP hyperthermia treatment into clinical development.
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe
diagnostic imaging technology. Combining biotechnology and
nanotechnology, the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion
Biosystems listed on the Australian Securities Exchange (ASX) in June
2017.
For further information please visit www.imagionbiosystems.com
3
Australian Media & Investor Relations
Evonne Grosso, WE Communications
we-auimagionbiosystems@we-worldwide.com
+61-450-603-182
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Share your feedback
Discover